Announcements Trials
Browse Landscape

Status

Completed 13Terminated 4No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

nilotinib 4dabrafenib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3Nivolumab 3tazemetostat 2talimogene laherparepvec 2ceritinib 2TIC10 compound 2Suspensions 2Prednisone 2Powders 2Panobinostat 2Melphalan 2Lenalidomide 2Ipilimumab 2Everolimus 2Dexamethasone 2Crizotinib 2Bortezomib 2Bevacizumab 2Axitinib 2zanubrutinib 1zanidatamab 1venetoclax 1veliparib 1tucatinib 1talquetamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × talimogene laherparepvec × Clear all
NCT02297529 2019-10-31

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Amgen

No longer available
Dermatologic

Melanoma

NCT02147951 2016-03-01

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Amgen

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡